secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cabaletta Bio, Inc. (CABA)
CIK:        0001759138
Form:       8-K
Filed at:   2025-06-11T23:59:59+00:00
Accession:  0001193125-25-138737
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 1.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cabaletta Bio reports strong rese-cel efficacy data in myositis, SLE, and scleroderma at EULAR 2025
--------------------------------------------------------------------------------

- 7 of 8 myositis patients achieved clinical response off all immunomodulators; all 4 ASyS/DM patients achieved meaningful TIS response.
- All 7 SLE patients achieved clinical response off immunomodulators and glucocorticoids; all non-renal SLE patients achieved DORIS.
- Both scleroderma patients showed meaningful mRSS improvements after discontinuing all immunomodulators and steroids, sustained to 6 months.
- In 18 patients with ≥4 weeks follow-up, 94% had no or Grade 1 CRS; 89% had no ICANS; enrollment accelerated to 51 patients actively enrolled.
- Company terminated ATM program with TD Cowen; prior sales of ~2.6M shares for $7.9M gross proceeds; $192M unused capacity cancelled.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1759138/000119312525138737/0001193125-25-138737-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1759138/000119312525138737/d78097d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-138737

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer